From: SSEP N20 and P25 amplitudes predict poor and good neurologic outcomes after cardiac arrest
Se(%) | Sp(%) | FPR(%) | |
---|---|---|---|
N20-baseline > 2 µV | 39 (33–44) | 73 (68–78) | 27 (22–32) |
N20-baseline > 2.7 µV | 28 (23–33) | 87 (83–91) | 13 (9–17) |
N20–P25 > 3,2 µV | 29 (23–34) | 93 (90–96) | 7 (4–10) |
N20–P25 > 4 µV | 14 (10–18) | 95 (92–97) | 5.4 (3–8) |
No status myoclonus | 94 (92–97) | 56 (51–62) | 44 (38–49) |
Day 3 NSE peak < 60 µg/ml | 93 (90–96) | 74.5 (69–80) | 25.5 (20–31) |
Benign EEG | 89 (85–92) | 86 (82–90) | 14 (10–18) |
N20-baseline > 2 µV + benign EEG | 33.3 (28–39) | 96.9 (95–99) | 3.1 (1–5) |
N20-baseline > 2 µV + NSE < 60 ng/ml | 28 (23–33) | 90.6 (87–94) | 9.4 (6–13) |
N20-baseline > 2 µV + no status myoclonus | 33.3 (28–39) | 86 (82–90) | 14 (10–18) |
N20–P25 > 3.2 µV + benign EEG | 17 (13–21) | 97 (93–98) | 3 (2–7) |
N20–P25 > 3.2 µV + day 3 NSE < 60 µg/ml | 17 (13–21) | 98.4 (97–100) | 1.6 (0–3) |
N20–P25 > 3.2 µV + No status myoclonus | 17 (13–21) | 95.3 (93–98) | 4.7 (2–7) |